Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qianlieweitong Granules is a traditional Chinese medicine (TCM) botanical drug candidate developed for the treatment of Type III chronic prostatitis, specifically targeting damp-heat stasis and kidney deficiency syndromes. It is formulated as granules for oral administration. The drug is designed to improve symptoms associated with chronic pelvic pain syndrome (CPPS) by potentially addressing inflammation and microcirculation in the prostate gland. It has been evaluated in Phase II clinical trials in China, sponsored by the Jilin Province Innovative Pharmaceutical Public Service Platform.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qianlieweitong granules.